Effect of Sublingual Supplementation with Resveratrol in patients with Renal Disease

Not Applicable

• Conditions: Chronic Kidney Disease; Hemodialysis; Inflammation; Oxidative stress.; N18.0; E02.870.300; C23.550.470; G03.673

• Registration Number: RBR-43mg87
• Lead Sponsor: niversidade do Sul de Santa Catarina

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-10-17
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients of both sexes; over the age of 19; diagnosis of chronic kidney disease and who have been on a regular hemodialysis program for at least 3 months, since this is the time used to confirm the chronicity of renal disease

Exclusion Criteria

Patients with a history of hypersensitivity to resveratrol will be excluded from the study; patients with food allergy containing resveratrol;cancer patients; with acute renal failure; in use of anti-inflammatory drugs; use of omega 3 supplementation; bedridden patients

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Expected outcome 1:<br>Reduction of serological inflammatory markers, verified by turbidimetry methods and enzyme-linked immunosorbent assay (ELISA), of at least 10%. Data collected before the intervention and 30 days after the intervention.<br>;Expected outcome 2:<br>Reduction of serological oxidative stress markers, measured by spectrophotometry, of at least 10%. Data collected before the intervention and 30 days after the intervention.

Secondary Outcome Measures

Name	Time	Method
Expected outcome 1:<br>Improvement of the quality of life, evaluated by the questionnaire quality of life for chronic kidney disease, of at least 20%. Data collected before the intervention and 30 days after the intervention.<br> <br>